Collaboration with CSEM will speed up identification of suitable soluble TCR candidates Engimmune’s executive team will be presenting at Biotech Showcase in San Francisco in January Basel, Switzerland, December 13, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased to announce that it […]
Offering includes participation from both new and existing healthcare-dedicated investors Proceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) — IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has […]
Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]
